Post-earnings recap
Reported
Thu, May 4, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
50%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Kymera Therapeutics reported a larger-than-expected loss per share, which contributed to a significant drop in stock price. The lack of revenue figures and guidance left investors uncertain about the company's future prospects. The stock's decline reflects these concerns and the overall market reaction to the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.70 | N/A | -0.86% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about ongoing project developments. They did not offer any updates on future guidance, indicating uncertainty.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in its current projects.